CDM 050

Drug Profile

CDM 050

Alternative Names: CDM050

Latest Information Update: 30 Jan 2017

Price : $50

At a glance

  • Originator Kao Corporation
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Skin disorders

Most Recent Events

  • 16 Jan 2017 Kao Corporation plans a phase I trial for skin disorders in North America (UMIN000025668)
  • 01 Jan 2017 Preclinical trials in Skin disorders in Japan (Topical) before January 2017 (UMIN000025668)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top